ARTICLE | Clinical News
RO5024048: Phase II delayed
March 1, 2010 8:00 AM UTC
Pharmasset said partner Roche no longer plans to conduct the planned 12-week Phase II INFORM-2 trial to evaluate twice-daily 1,000 mg oral RG7128 plus oral RG7227 with and without pegylated interfero...